BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy

BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.

For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.

Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.

You May Also Be Interested In

• Canaccord Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
• BofA's Hartnett explains why Wall Street is trading with 'no fear'
• Applied Materials (AMAT) PT Lowered to $650 at BofA Securities, 'our top semicap pick is LRCX'